Novo Nordisk is in a buy zone after a 39% gain year to date. The anti-obesity drug market is expect to grow to $4.4 billion by 2032.
Netflix and Novo Nordisk are just two names on this smorgasbord of stocks setting up or soaring past new buy points.
As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.